Anatomical and Functional Outcomes of Vitrectomy with/without Intravitreal Methotrexate Infusion for Management of Proliferative Vitreoretinopathy Secondary to Rhegmatogenous Retinal Detachment

Table 7

Review of studies on PPV and adjuvant methotrexate for proliferative vitreoretinopathy complicating rhegmatogenous retinal detachment.

Author	PVR grade	Surgical technique	No. of eyes	Retinal reattachment (%)	Final BCVA
Sadaka et al. [7]	PVR C	PPV + MTX infusion + SF6/C3F8/silicone oil	29	90% (single surgery)	66% ≥ 20/200
Benner et al. [8]	PVR C	PPV + extended PFCL tamponade + 5 bi-weekly MTX injections (100–200 μg/0.05 mL)	5	100%	80% > 20/200
Nourinia et al. [16]	PVR C	PPV + intra-silicone oil injection of MTX 250 μg (3 injections, 3-week interval)	11	82% total reattachment	∼6 lines gain
				18% reattachment posterior to the equator
				Silicone oil was not removed in 82% of patients
Falavarjani et al. [17]	PVR C	PPV + single intrasilicone oil injection of MTX 250 μg	22 (treatment arm)	95.5%	No statistically significant difference between groups
			22 (control arm)	77.3%
Current study, 2020	41.5% PVR C	PPV + MTX infusion + C3F8/silicone oil	42 (PVR C)	74% (single surgery)	4 lines mean gain 54% ≥ 0.1, 11% ≥ 0.4
	35% high risk of PVR		35 (high risk of PVR)	77% (single surgery)
			24 (no risk of PVR)	96% (single surgery)
	24% no risk of PVR

BCVA, best-corrected visual acuity; C3F8, octafluoropropane; μg, microgram; mL, milliliter; MTX, methotrexate; No., number; PFCL, perfluorocarbon liquid; PPV, pars plana vitrectomy; PVR, proliferative vitreoretinopathy; SF6, sulfurhexafluoride.